Regenxbio and AbbVie announced positive Phase II results for gene therapy ABBV-RGX-314 in wet AMD, showing a 97% reduction in ...

Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections. Read why I'm neutral on ABBV ...

Chicago, IL – October 22, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

Regenxbio (RGNX) announced positive data from the Phase II fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314 in patients ...

Monday announced that nine provinces have approved accelerated public coverage of Epkinly, a treatment for adult ...

The global kinase inhibitor in autoimmune diseases market is projected to grow steadily over the next decade, according to a ...

Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...

From Fortune 500 firms to startups, Crain's exclusive list reveals the Chicago-area companies inventing new ways of doing ...

AbbVie (NYSE:ABBV – Free Report) had its target price upped by BMO Capital Markets from $214.00 to $220.00 in a research note ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...